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High-fat diet (HFD) induces obesity. This study examined the eﬀects of Shiitake mushroom on the prevention of alterations of
plasma lipid proﬁles, fat deposition, energy eﬃciency, and body fat index induced by HFD. Rats were given a low, medium, and
high (7, 20, 60g/kg = LD-M, MD-M, HD-M) Shiitake mushroom powder in their high-fat (50% in kcal) diets for 6 weeks. The
results showed that the rats on the HD-M diet had the lowest body weight gain compared to MD-M and LD-M groups (P<0.05).
The total fat deposition was signiﬁcantly lower (−35%, P<0.05) in rats fed an HD-M diet than that of HFD group. Interestingly,
plasma triacylglycerol (TAG) level was signiﬁcantly lower (−55%, P<0.05) in rats on HD-M than HFD. This study also revealed
the existence of negative correlations between the amount of Shiitake mushroom supplementation and body weight gain, plasma
TAG, and total fat masses.
1.Introduction
Obesity is a chronic health problem. It is predicted that
by 2015 approximately 2.3billion adults will become over-
weight, and more than 700million will be obese [1].
Obesity causes many complications including dyslipidaemia,
diabetes, hypertension, and heart disease. Recently, obesity
has also been associated with the increased incidence of
many cancers [2]. Dyslipidaemia is a pathological disorder,
and current evidence has highlighted not only total choles-
terol but also triacylglycerol (TAG) as lipid risk factors in
metabolic syndrome.
Recently, community awareness in nutrition as a corner-
stone for healthy life style has increased. Functional food is
a concept of nutrition, based on the role of reducing the risk
of disease. A food will be considered as a functional food if
it gives one or more beneﬁts or positive eﬀects to the body
beyond adequate nutritional eﬀects in a way that is relevant
to either improve the stage of health and well-being and/or
reduce the risk of disease [3].
Shiitakemushroomsarethesecondmostpopularandthe
third widely cultivated edible mushroom in the world [4].
Certain components of Shiitake mushroom have hypolipi-
daemic eﬀect, such as eritadenine and β-glucan. Although it
has been reported that eritadenine extracted from Shiitake
mushroom has hypolipidaemic eﬀect, most of these studies
emphasize on the mechanism in hypocholesterolaemic eﬀect
[5–8] but not the eﬀect on triglyceride. β-glucan from
Shiitake mushroom is a primarily soluble dietary ﬁbre. β-
glucan also present at high levels in graminaceous crops
such as barley, rye, and oat and also in bacteria, fungi,
and edible mushrooms [9], but the structure can vary from
source to source. Studies have reported that oat β-glucan
can increase satiety, reduce food intake, delay nutrition
absorption,andreduceplasmalipidlevels[10–12].Although
mushroom has been shown to improve lipid proﬁles [13–
15], studies in this regard are incomplete. Some studies have
reported single-dose eﬀect on obesity-associated metabolic
disorders using mushroom powder supplementation [13,
16–18]. However, no data are currently available on the
ability of Shiitake mushroom to aﬀect food intake, body fat
deposition, and plasma triglyceride concentrations in a dose
response manner.2 Journal of Obesity
Studies have shown that high-fat diet-induced obesity in
rodents can develop dyslipidaemia, insulin resistance, and
altered metabolic regulatory hormones [19–22]. The diet-
induced obese animal model mimics human obesity more
than other models such as genetic knockout mutants [23].
This study has systematically examined the eﬀects of Shiitake
mushroom on plasma lipid proﬁles, various types of fat
depositions, energy eﬃciency, and body fat index as well as
their relationships in a dose-response manner in rats fed a
high-fat diet.
2.MaterialandMethods
2.1. Animals and Diet. A l le x p e r i m e n t a lp r o c e d u r e sw e r e
approved by the Animal Ethics Committee of the University
ofWollongong,AE09/01.FortyWistarrats,at9weeksofage,
were obtained from animal resource centre (ARC)-Perth,
Western Australia, and were given one week acclimatization
to their new environment. They were housed two per cage in
environmentally controlled conditions (temperature 22◦C,
light cycle from 06:00 to 18:00 hours, and dark cycle from
18:00 to 06:00 hours) and had ad libitum access to food
and water. All rats were fed standard laboratory nonpuriﬁed
diet (YS Feeds PTY-Ltd, Young, NSW, Australia) during the
acclimatization period. The forty rats were divided into four
groups (n = 10) and fed 50% high-fat diets with an addition
of nil, low, medium, or high-dose of Shiitake mushroom
powder (HFD, 7g/kg LD-M, 20g/kg MD-M, or 60g/kg HD-
M, resp.). The dietary intervention was carried out for six
weeks. The food was produced from semisynthetic material
according to the recommendation of American Institute of
Nutrition AIN-93 for rodent [24]. HFD consisted of the
following (g/Kg): corn starch, 210 (Goodman Fielder, NSW,
Australia); sucrose, 175 (Bella-vista, NSW, Australia); copha,
105 (Peerless food, Victoria, Australia); lard, 105 (Fonterra
brand, Victoria, Australia); sunﬂower oil, 50 (Goodman
Fielder, NSW, Australia); gelatine, 50 (Sunny Hills, Qld, Aus-
tralia); casein, 128 (Fonterra LTD, Auckland, New Zealand);
ﬁber, 51 (Nature, Rosenberg, Germany); mineral, 67 (MP
Biomedical, Ohio, USA); vitamin, 13 (MP Biomedical,
Ohio, USA). This study used Shiitake mushroom powder
containing 30%β-glucan (w/w) analysed with a Megazyme
β-glucan Kit. Compositions of the four diets are shown in
Table 1.
2.2. Food Intake, Body Weight, and Body Composition. Ani-
mals were weighed weekly throughout the six-week inter-
vention period. Food intake was measured every 24hours
by weighing the amount of total food (g) provided to the
rats and subtracting the remaining food (g) in the cage after
24hours. Following the intervention period, rats were killed
via carbon dioxide asphyxiation. The white adipose tissue
(WAT) comprised of visceral fat (epididymal, perirenal, and
omental fat) and subcutaneous fat (inguinal fat) and brown
adipose tissue (BAT) were then dissected out and weighed.
The body fat index (BFI) was calculated as the total amount
of epididymal, perirenal, omental, and inguinal fat deposits
per100gbod yw eight[25].Theenergyeﬃciencyratio(EER)
Table 1: Composition of experimental diet.
Component
Group1
HFD LD-M MD-M HD-M
C a r b o h y d r a t e ( % ) 3 23 33 33 4
Protein (%) 16 16 16 16
Fat (%) 50 49 49 48
F i b r e ( % ) 2223
Shiitake mushroom powder
%( w t:w t ) —0 . 7 2 6
Energy density (kJ/g) 18.8 18.8 18.8 18.4
1HFD: high-fat diet; LD-M: low-dose mushroom in HFD; MD-M: medium
mushroom in HFD; HD-M: high-dose mushroom in HFD.
was calculated by body weight gain (BWG) per the amount
of energy intake (g/kJ) [26].
2.3. Plasma Lipid Proﬁle. Blood samples were obtained by
puncturing the right ventricle of heart after euthanasia and
were collected in ethylenediaminetetraacetic-acid- (EDTA-)
coated tubes and centrifuged at 3000×rpm at 22◦Cf o r
25minutes. High-density lipoprotein (HDL) was isolated
fromplasmawithdextransulphateandmagnesiumchloride,
based on a modiﬁed method from Sjoblom and Eklund [27].
Total plasma cholesterol (TC), TAG and HDL cholesterol
were measured using the Konelab 20XT with Inﬁnity reagent
from Thermo Fisher Scientiﬁc (Auburn NSW, Australia).
2.4. Statistical Analysis. Food intake, BWG, EER, BFI, adi-
pose tissue, and plasma lipids were presented as mean and
standard errors. Statistical analysis was performed using
SPSS software (version 17.0, SPSS Inc, Chicago, Ill, USA).
One-way ANOVAs were used, followed by a post hoc Tukey-
Kramer signiﬁcant diﬀerences test for multiple comparisons
among the groups. Diﬀerences were considered signiﬁcant
when P<0.05.
3. Results
3.1. Food Intake, Body Weight, and Fat Deposition. No dif-
ferences in the amount of food or energy intake were found
among all groups (Table 2). This study found signiﬁcant
eﬀects of dietary intervention on body weight gain (F3,38 =
6.204, P = 0.002, Table 2). Rats on a high dose of Shiitake
mushroom diet (HD-M group) had −35% and −39% lower
body weight gains than rats on low- and medium-Shiitake
mushroom diets, respectively (P<0.05). There was also
a trend of lower body weight gain in the HD-M group
compared with the HFD group (−23%, P = 0.077).
Overall, there were signiﬁcant eﬀects in total fat masses
due to dietary interventions (F3,38 = 4.355, P = 0.010,
Table 2). Rats on HD-M diet had signiﬁcantly lower total fat
masses, −35% and −37%, than the HFD and LD-M groups,
respectively. Furthermore, HD-M group also had a trend of
lower fat accumulation than the MD-M group (−32%, P =
0.076, Figure 1). The white adipose tissue in MD-M group
was−35%and−37%lowerthantheHFDandLD-Mgroups,Journal of Obesity 3
Table 2: Food intake, energy intake, body weight, and fat deposits of rats fed experimental diets for 6 weeks1.
Treatment group
ANOVA
HFD LD-M MD-M HD-M
Food intake (g/rat/day) 24 ±0.52 4 ±0.52 4 ± 0.62 3 ±0.8 NS
Energy intake (kJ/rat/day) 455 ±9 449 ±9 448 ±11 423 ±14 NS
Body weight gain 129 ±8a,b 141 ±9b 150 ±14b 92 ± 8a 0.002
Fat-pad masses (g)
Epididymal 11.2 ±1.0a,b 12.1 ±1.0b 11.4 ± 1.2a,b 7.9 ±0.5a 0.014
Perirenal 14.2 ±1.1a 14.3 ±1.7a 12.8 ± 1.6a,b 8.7 ±0.8b 0.015
Omental 8.4 ±0.6a,b 10.5 ±1.0a 8.5 ±0.7a,b 6.7 ±0.6b 0.009
Inguinal fat 8.6 ±1.5a 6.8 ±0.7a,b 8.2 ±1.7a 4.2 ±0.5b 0.012
Visceral fat 33.8 ±2.3a,b 37.0 ±3.7b 34.0 ± 3.7a,b 23.3 ± 1.7a 0.012
WAT 42.4 ±3.4a 43.8 ±4.3a 40.6 ± 4.5a,b 27.5 ±2.1b 0.011
BAT 0.58 ±0.05 0.52 ±0.06 0.54 ±0.05 0.44 ±0.01 NS
Total fat masses 43.0 ±3.4a 44.4 ±4.3a 41.2 ± 4.5a,b 28.0 ±2.1b 0.010
1Values are means±SEM, n = 10. Within a row, values with diﬀerent superscripts are signiﬁcantly diﬀerent, P<0.05. Abbreviations used: HFD: high-fat diet;
LD-M: low-dose mushroom in HFD; MD-M: medium mushroom in HFD; HD-M, high-dose mushroom in HFD.
respectively (F3,38 = 4.340, both P<0.05). The visceral
fat mass (epididymal + perirenal + omental) was the lowest
in the HD-M group among all groups (F3,38 = 4.215, P =
0.012, Table 2). Furthermore, HD-M group had signiﬁcantly
lower perirenal (−39%) and inguinal fat (−52%) compared
to HFD group. Epididymal and omental fat masses were
29% and 21% lower in the HD-M group than HFD group
(P = 0,05). No diﬀerences were found in the BAT masses
among all groups.
3.2. Body Fat Index (BFI) and Energy Eﬃciency Ratio (EER).
The BFI was signiﬁcantly diﬀerent between four diet groups
(F3,38 = 5.86; P = 0.002). Results showed that rats on a HD-
M diet had a signiﬁcantly lower BFI than the rats on HFD,
LD-M, and MD-M diets (−35%, −33%, and −30%, resp.).
No diﬀerences were found in the BFI between the HFD, LD-
M, and MD-M groups (Figure 2). There was a signiﬁcant
diﬀerence in EER among four diet groups (F = 5.425,
P = 0.004, Figure 3). The HD-M group had a signiﬁcantly
lower EER than the LD-M and MD-M groups (−30% and
−34%, resp.) but was not signiﬁcantly diﬀerent from HFD.
Furthermore, there were no statistical diﬀerences in EER
between the HFD, LD-M, and MD-M groups.
3.3. Plasma Triacylglycerol, Cholesterol and HDL Concentra-
tions. TherewasasigniﬁcantdiﬀerenceinplasmaTAGlevels
between the four groups (F3,38 = 7.445; P = 0.001). The rats
on the HD-M diet had signiﬁcantly lower levels of TAG than
HFD, LD-M, and MD-M (−55%, −41%, and −46%, resp.).
There were no signiﬁcant diﬀerences among the HFD, LD-
M, and MD-M groups (Figure 4). Plasma total cholesterol
levels did not diﬀer between four groups (P = 0.125).
Although rats on an HD-M diet had the highest level of
plasma HDL, no statistical diﬀerence was found (HD-M:
HFD: LD-M: MD-M = 1.26 ±0.01: 1.12 ±0.02: 0.95 ±0.02:
0.84 ±0.01mmol/L), respectively.
3.4. Association between the Dosages of Shiitake Mushroom
and BWG, WAT, Plasma Lipid, BFI, and EER. This study
found that the amount of Shiitake mushroom added in a
high-fat diet (50% fat in kcal) was negatively associated
with the BWG, WAT, TAG, BFI, and EER (Figure 5). No
statistical diﬀerence was found between the amount of
Shiitake mushroom diets and plasma cholesterol and HDL
concentrations (data not shown).
4. Discussion
This study showed that adding HD-M in a high-energy
diet containing 50% fat can signiﬁcantly prevent total fat
deposition and signiﬁcantly lower plasma TAG in rats
compared with no addition of Shiitake mushroom diet.
It was also found that plasma TAG-lowering eﬀect was
negatively associated withthe amountof Shiitake mushroom
supplementations and positively associated with the amount
of visceral fat. Studies have been carried out to test plasma
TAG-lowering eﬀect by adding mushroom powder into the
diets. The results varied, where studies showed a signiﬁcant
eﬀect of lowering plasma TAG [14, 15, 18, 28, 29], whilst
other did not [17, 30, 31]. There are a few factors that
may explain these diﬀering results. The ﬁrst is related to
the amount of sucrose in the diet which can lead to a high
level of plasma TAG in rodents [17, 18]. High-sucrose diet
promotes a hyper-TAG plasma level by increasing hepatic
TAG secretion and decreasing TAG removal [32]. A previous
study has reported that if the sucrose amount in the diet
is greater than 40% from total energy, the increasing of
plasma TAG is diﬃcult to prevent by enriched mushroom
powder diet [17]. In this study, the high-fat diet group as
controls supplied 15% sucrose from total energy. Second is
the amount of mushroom in the diet. Studies have shown
that adding less than 5% (wt:wt) mushroom powder in the
diet does not signiﬁcantly decrease plasma TAG, irrespective
the sources [13, 14, 17, 18, 30, 31, 33], which is also what4 Journal of Obesity
a
a
a, b
b
0
10
20
30
40
50
60
HFD LD-M MD-M HD-M
T
h
e
t
o
t
a
l
f
a
t
m
a
s
s
e
s
(
g
)
Figure 1: Total fat masses were measured after 6-week dietary
treatments in rats. Bars represent means ± standard errors, n = 10.
abMeans not sharing a common letter are signiﬁcantly diﬀerent
among groups at P<0.05.
we have found. Therefore, the ratio between the amount of
sucrose and enriched mushroom in the diet is important for
plasma TAG-lowering eﬀect.
The duration of the dietary intervention using mush-
room powder seems less important as it is compared with
the dose. Some short-term studies, 3 to 5 weeks [18, 33],
reported a reduction of plasma TAG concentration, whilst
others [16–18]r e p o r t e dn oe ﬀects. Likewise, the longer-
interventionstudies,suchas6-to10-weekinterventions,also
showed mixed results with some having no eﬀect [31]a n d
others with positive outcomes to prevent increasing plasma
TAG levels [15, 30]. Hence, the dose of mushroom powder is
more important than duration of supplementation.
Itislargelyunreportedtousefatmassesasanindicatorto
determine the eﬀect of adding mushroom to a diet on body
weight gain. In animal studies, there are currently limited
data relating to the analysis of body fat masses. Kabir and
Kimura [30] reported that giving 5% Shiitake mushroom
and 5% Maitake mushroom for 8weeks to spontaneous
hypertensive rats (HSRs) did not signiﬁcantly lower adipose
tissuecomparedtocontrolgroup.Thereisalsoalackofstudy
to deﬁne the eﬀect of mushrooms on total fat masses in the
human study. In this study, we have demonstrated that the
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Figure 2: Body fat index was measured after 6-week dietary
treatments in rats. Bars represent means ± standard errors, n = 10.
abMeans not sharing a common letter are signiﬁcantly diﬀerent
among groups at P<0.05.
high-dose Shiitake mushroom lowered total fat deposition.
In addition, there was a negative correlation between an
increased dosage of Shiitake mushroom and a lower body fat
index. Previous study reported that reducing of plasma TAG
is associated with the decrease of total fat masses as white
adipose tissue [34], which is consistent with our results.
Weight-loss interventions are commonly prescribed for
obesity to reduce risk factors associated with metabolic
disease. Studies from animal experiments showed various
results in terms of adding mushroom powder in diets
aﬀecting body weight gain and obesity. For example, a study
[14]showedadecreaseinbodyweightgainby53%byadding
2% extracts of Agaricus Blazei mushroom in the diet for
6weeks in diabetes mellitus Sprague-Dawley rats induced
by streptozotocin. Again, body weight gain was signiﬁcantly
reduced by 25% when adding 20% Maitake mushroom
powder to a hypercholesterolemic diet for 25 weeks [33].
However,nostatisticaldiﬀerenceinbodyweightchangeswas
reported in ApoE−/− mice after being given a diet containing
3% Bunashimeji mushroom powder for 10wks [31]. A
similar result also reported that additional 5% mushroom
powder in the diet for four or eight weeks had no eﬀect on
lowering body weight gain in spontaneous hypertension ratsJournal of Obesity 5
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Figure 3: Energy eﬃciency ratio (EER) was measured after 6-week
dietary treatments in rats. Bars represent means ± standard errors,
n = 10. For each variable, labelled means without a common letter
diﬀer, P<0.05.
or male F344/DuCrj rats [17, 30]. It appears that diﬀerent
species of animal respond diﬀerently in body weight gain
to the dietary intervention using mushroom powder. The
dosageslessthan5%mushroompowderseemtobelesslikely
to give any favourable eﬀecttopreventbodyweightgain.The
initial body weight and age of animal model seem to have no
aﬀect on the outcome of mushroom treatment to prevent the
increase of body weight [16–18, 30].
This study showed that body weight gain was signiﬁ-
cantly lower in the HD-M group than the MD-M and LD-
M groups. This suggests that there was a threshold eﬀect in
terms of the amount of Shiitake mushroom intake for the
prevention of weight gain in rats on a high-fat diet. As an
estimate of HD-M diet in rats, 90g mushroom powder per
day may be required for humans to prevent body weight gain
a n dl o w e rT A G .H o w e v e r ,t h i sm u s tb et e s t e di nh u m a n s
before the recommendation is given. On the other hand,
a low-dose mushroom diet may not be strong enough to
prevent weight gain. For example, studies have shown that
supplementation of the diet with 30g Maitake mushroom
per day for 21 days did not achieve body weight lowering
eﬀect in patients with moderate dyslipidaemia [35].
This study found a diet of HD-M signiﬁcantly lowered
the energy eﬃciency ratio (EER) compared to LD-M and
HFD LD-M MD-M HD-M
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Figure 4: Plasma TAG level was measured after 6-week dietary
treatments in rats. Bars represent means ± standard errors, n = 10.
For each variable, labelled means without a common letter diﬀer,
P<0.05.
MD-M diets. The HD-M also tended to lower EER when
compared with HFD. This is in agreement with a previous
studyshowingthathigh-doseShiitakemushroomdietlowers
energy eﬃciency in rats on a high-fat diet as adding Maitake
mushroom (20%) into hypercholesterolemic diet for 4 weeks
reduces 27% energy eﬃciency in body weight gain in rats
[33]. Unfortunately, the study of this kind has not been
carried out in humans.
The exact mechanism is not clear how Shiitake mush-
room diet resulting in lowering body weight gain, fat masses
and plasma TAG. There are three possible mechanisms
worthwhile of considerations. Firstly, Shiitake mushroom
could increase the fat elimination into faeces. Shiitake
mushroom contains 30%β-glucan. As a soluble ﬁbre, β-
glucan may enhance luminal viscosity, delay gastric empty-
ing, and/or reduce intestinal absorption. Hence, it decreases
fat absorption. Secondly, Shiitake mushroom could reduce
nonesteriﬁedfattyacid(NEFA)derivedfromTAGasasource
of adipose tissue. Lipolysis of chylomicron and VLDL-TAG
are major determinants of adipose tissue development, and
the reduced WAT may be aﬀected by the low-NEFA source
that enters to adipose tissue. A low NEFA in adipose tissue is6 Journal of Obesity
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Figure 5: Signiﬁcant correlations were found between dosages and BWG (a), WAT (b), plasma TAG level (c), BFI (d), and (e) EER. BWG:
body weight gain; WAT: white adipose tissue; TAG: triacylglycerol; BFI: body fat index; EER: energy eﬃciency ratio.Journal of Obesity 7
possibly aﬀected by the activity of enzyme LPL as main gate
keeper entry into adipose tissue [34]. The overexpression of
LPL in muscle prevents HFD-induced lipid accumulation
in adipose tissue. Increased LPL in skeletal muscle leads
to an enhanced TAG storage in muscle and then diverts
lipoproteinTAG-derivedNEFAawayfromstorageinadipose
tissue to oxidation in the muscle [36]. Normally fat from
food is released into the circulation as lipoprotein-TAG
[34]. Thirdly, the possibility that eritadenine from Shiitake
mushroom could inhibit the release of triacylglycerol from
the liver. The eritadenine has been reported to inhibit the
productionofphosphatidylcholinethatinﬂuencestherelease
ofVLDLandHDLfromliver[5].Studiesshowedthatadding
eritadenine extracted from Shiitake mushroom in the diet
can decrease plasma TAG by 27% in a cholesterol diet,
20% in cholesterol free diet, and 2% in diet with choline
chloride added [5–7]. The 50mg eritadenine per kg diet
was shown to be suﬃcient to elicit hypolipidaemic eﬀect in
rats [8]. The concentration of eritadenine is about 0.36% in
Shiitake mushroom powder [37]. The HD-M diet used in
this study contains ∼200mg/kg food. Since TAG was low in
HD-M diet, it will be interesting to examine TAG in various
organs to ensure its possible storage or exclusion. In view of
that, fat content in faecal, plasma NEFA concentration, and
accumulation of TAG in the liver and muscle will need to be
examined to verify its potential side eﬀects.
In conclusion, adding high Shiitake mushroom in a
high-fat diet can prevent body weight gain, fat deposition,
and plasma TAG in rats, while further study is necessary
to elucidate the underlying mechanisms and the possibility
componentofShiitakemushroomoftheseimportanteﬀects.
T h e r e b y ,i tc o u l db eu s e da saf u n c t i o n a lf o o dt op r e v e n t
obesity. This study encourages an eﬀort pursuing human
clinical trial using Shiitake mushroom for prevention and
treatment of obesity and its related metabolic disorders.
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